News | May 14, 2024
Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden
Good momentum in commercial CDMO business
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Subscribe To Our Newsletter & Stay Updated
